Ca-AKG: The Longevity Molecule That Declines 10-Fold With Age
Alpha-ketoglutarate (AKG) is a natural metabolite involved in energy production and the control of gene activity, and blood levels fall about 10-fold between ages 40 and 80, which made restoring it a testable anti-aging idea. The promise rests mostly on early data: calcium-AKG extended lifespan and sharply reduced frailty in middle-aged mice, and a small uncontrolled human study reported an 8-year drop in “biological age” on a methylation test — but that study had no placebo group and used a biomarker, not a real health outcome. Typical doses are 1,000–3,000 mg/day with food, and because the products are essentially identical commodity Ca-AKG, price differences reflect marketing rather than chemistry. It is best viewed as a promising but still-unproven option for adults over 50 targeting metabolic and inflammatory markers, never a substitute for exercise, sleep, and protein; people with high calcium or on calcium-restricted diets should check with a clinician.
The Mouse Data That Launched the Category
A 2020 study in Cell Metabolism (Asadi Shahmirzadi et al., PMID 32877690) showed that Calcium AKG (CaAKG) supplementation starting at middle age in C57BL/6 mice extended median lifespan in females (the published survival curves correspond to roughly a 10–12% extension) and, more importantly, compressed morbidity: a frailty index fell across multiple aging parameters even when raw lifespan gains were modest. The authors proposed that CaAKG suppresses chronic inflammation in part by inducing IL-10, lowering systemic TNF-α and IL-6.
The First Human Epigenetic Data
A 2021 retrospective open-label analysis in Aging (Demidenko et al., PMID 34847066) examined 42 adults taking Rejuvant® (a formulation of CaAKG plus retinyl palmitate and vitamin D3) for an average of 7 months. Participants showed an average decrease in biological age of 8 years on the TruAge DNA methylation test (p ≈ 6.5×10−12). Caveats are large: no placebo arm, retrospective selection, and epigenetic age is a biomarker rather than a hard outcome. But the signal generated enough interest to motivate placebo-controlled replication, which is now in progress.
Dosing and Limitations
Common human doses are 1,000–3,000 mg/day of Ca-AKG, typically taken with food. The calcium content is modest but should be counted toward total intake. AKG is not patentable; most products are identical commodity Ca-AKG, and price variation reflects marketing rather than chemistry. AKG is well-tolerated in published trials, but anyone with hypercalcemia or on calcium-restricted diets should discuss use with a clinician.
Realistic Expectations
Ca-AKG is one of the more promising longevity interventions with a plausible mechanism and encouraging early human data, but controlled trials with hard endpoints are still in progress. Treat it as an evidence-accumulating supplement, not a proven longevity therapy. Its best use case is in adults over 50 targeting metabolic and inflammatory markers of aging, alongside exercise, sleep, and protein intake — which still outperform any supplement.
Sources
- Asadi Shahmirzadi A, et al. "Alpha-Ketoglutarate, an endogenous metabolite, extends lifespan and compresses morbidity in aging mice." Cell Metabolism, 2020. PMID 32877690.
- Demidenko O, et al. "Rejuvant®, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging, after an average of 7 months of use, in the TruAge DNA methylation test." Aging (Albany NY), 2021. PMID 34847066.
- Chin RM, et al. "The metabolite alpha-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR." Nature, 2014. PMID 24828042.
- Su Y, et al. "Alpha-ketoglutarate and the regulation of mammalian aging." Mechanisms of Ageing and Development, 2019.